Next Article in Journal
Morin Hydrate Reverses Cisplatin Resistance by Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular Carcinoma
Next Article in Special Issue
Transarterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin-Loaded Tandem Drug-Eluting Embolics
Previous Article in Journal
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Previous Article in Special Issue
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
 
 
Article

Article Versions Notes

Cancers 2019, 11(7), 985; https://doi.org/10.3390/cancers11070985
Action Date Notes Link
article xml file uploaded 15 July 2019 13:09 CEST Original file -
article xml uploaded. 15 July 2019 13:09 CEST Update -
article pdf uploaded. 15 July 2019 13:09 CEST Version of Record https://www.mdpi.com/2072-6694/11/7/985/pdf-vor
article supplementary file uploaded. 15 July 2019 13:09 CEST - https://www.mdpi.com/2072-6694/11/7/985#supplementary
article html file updated 15 July 2019 13:11 CEST Original file -
article xml file uploaded 18 July 2019 08:06 CEST Update -
article xml uploaded. 18 July 2019 08:06 CEST Update https://www.mdpi.com/2072-6694/11/7/985/xml
article pdf uploaded. 18 July 2019 08:06 CEST Updated version of record https://www.mdpi.com/2072-6694/11/7/985/pdf
article supplementary file uploaded. 18 July 2019 08:06 CEST - https://www.mdpi.com/2072-6694/11/7/985#supplementary
article html file updated 18 July 2019 08:07 CEST Update -
article html file updated 2 August 2019 13:24 CEST Update -
article html file updated 13 February 2020 02:29 CET Update -
article html file updated 20 July 2022 06:58 CEST Update https://www.mdpi.com/2072-6694/11/7/985/html
Back to TopTop